41% ORR seen in squamous patients

ABRAXANE overall response rate in non-small cell lung cancer histologies subgroups Trial design

41% ORR seen in squamous patients

ABRAXANE overall response rate in non-small cell lung cancer histologies subgroups Trial design

INDICATION

ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.

INDICATION

ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.